Status:

UNKNOWN

TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis

Lead Sponsor:

University of Helsinki

Collaborating Sponsors:

Seinajoki Central Hospital

Oulu University Hospital

Conditions:

Rheumatoid Arthritis

Eligibility:

All Genders

18-60 years

Phase:

PHASE4

Brief Summary

The FIN-RACo trial is an investigator initiated multicenter (n=15 centers in Finland) prospective study on the treatment of patients with early rheumatoid arthritis (RA) with combination therapy with ...

Detailed Description

We want to study, whether early treatment with infliximab for 6 months started parallel with the combination therapy of methotrexate, sulphasalazine, hydroxychloroquine and prednisolone (COMBI) can in...

Eligibility Criteria

Inclusion

  • Diagnosis of RA fulfilling the ACR classification criteria for RA
  • Patients within age group of 18-60 years
  • Patients not permanently work disabled or retired
  • Duration of symptoms \< 12 months, and who have not received DMARD previously
  • Patients with active disease (see below)
  • Criteria for active disease at entry:
  • \> 6 swollen joints (66 joint count)
  • \> 6 tender joints (68 joint count)
  • duration of early morning stiffness \> 45 min and/or ESR \> 30 mm/h and/or CRP \> 20 mg/l

Exclusion

  • Previous treatment with DMARDs
  • Previous treatment with oral glucocorticoids during the previous 6 months
  • Less than 30 days from previous intra-articular injection with corticosteroids
  • Allergy to sulphonamides
  • Allergy to acetylsalicylic acid
  • Allergy to methotrexate
  • Allergy to antimalarials
  • Previous treatment with biologicals
  • Serum creatinine value \> upper limit of normal (registered in 2 different blood samples)
  • Serum transaminase levels \> 2x upper limit of normal (registered in 2 different samples)
  • Known/previous malignancy excluding basalioma or in situ cervical cancer \>5 years previously
  • Cardiac failure (NYHA III-IV)
  • Previous history of tuberculosis and/or exposition to tuberculosis and/or typical changes of previous/active tuberculosis in chest radiology
  • Active infection
  • Pregnancy
  • Leukopenia (WBC \< 4 x 109/l)
  • Thrombocytopenia (platelets \< 100 x 109/l)
  • Active peptic ulcer
  • Type I or type II diabetes under poor control
  • Heavy use of alcohol
  • Fertile women not practising contraception or who are planning pregnancy
  • Male patients wishing to have children during the therapy
  • Other autoimmune rheumatic disease
  • Other chronic disease which judged by the physician could influence the patient's compliance or intervene the study course
  • Patient is not cooperative

Key Trial Info

Start Date :

March 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2015

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT00908089

Start Date

March 1 2003

End Date

December 1 2015

Last Update

April 1 2015

Active Locations (13)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (13 locations)

1

Hämeenlinna Central Hospital

Hämeenlinna, Finland, FI-13530

2

Rheumatism Foundation Hospital

Heinola, Finland, FI-18120

3

Helsinki University Central Hospital

Helsinki, Finland, FI-00029 HUS

4

Orton Invalid Foundation Hospital

Helsinki, Finland, FI-00280

TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis | DecenTrialz